Microenvironment and Immunity of Digestive Cancers - East Paris Multicentric Cohort
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Tumor samples.
- Who it may be relevant to
- Registry conditions: Colorectal Cancer, Pancreas Tumor, Biliary Tract Tumor, Immune System and Related Disorders. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Interactions Between Tumor, Tumor Microenvironment and Immune System in Digestive Cancers : Impact on Survival and Response to Treatment
Overview
Colorectal and pancreatobiliary cancers are the most common digestive cancers. Their incidence has particularly increased over the last few decades, leading to suspicion that environmental factors are involved. In addition, strategies for the therapeutic management of these cancers are evolving in the context of the development of immunotherapies. Tumor microenvironment is a potential source of new diagnostic, prognostic and predictive markers and new therapeutic targets. The links between tumor microenvironment and modulation of the immune system in colorectal and pancreatobiliary cancers are poorly understood. Molecular classifications have been proposed for these cancers, but their link with immunity and response to treatment remains to be explored. Objective : explore links between molecular subtypes, tumor microenvironment, host (immune system, pre-metastatic niche, intestinal microbiota, metabolism), and survival (prognostic value), response (predictive value) and tolerance (toxicities) to treatments in digestive cancers, in particular colorectal and pancreatobiliary cancers. Method: Retrospective and prospective monocentric cohort study
Interventions
- Biological Tumor samples
for each patient: liver sampling, blood samples ( serum, plasma, PBMC, whole blood), per-endoscopic bile sampling, stool samples, and materials derived from fresh tumors
Primary outcome measures
- overall survival [Time frame: observation from first cancer treatment date until date of death or 10 years follow up if patient alive]
Eligibility criteria
Inclusion criteria
- Colorectal or pancreatic adenocarcinoma or biliary tract adenocarcinoma
- Cytologically or histologically proven adenocarcinoma, regardless of stage and treatment
- Age ≥ 18 years old
- Diagnosed from 2015 onwards
- Signed Consent
- Affiliation to a social security scheme (including CMU (Universal health coverage))
Exclusion criteria
- Patient under guardianship, curatorship or safeguarding of justice
- Pregnant or breastfeeding woman
- Any medical, psychological or social situation that could prevent compliance with the protocol according to the investigator's assessment.
- Refusal to participate in the study
- Patient on AME (state medical assistance)
- Persons deprived of liberty by a judicial or administrative decision
- Persons under psychiatric care
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT04707365 · APHP190090 · IDRCB :2019-A00071-56